Cannabinoids, Umbilical Cord Tissue
Use
Part of the Comprehensive Drug Screen profile for umbilical cord tissue, this assay specifically detects cannabinoids deposited in fetal umbilical cord tissue to assess in‑utero exposure to cannabis during approximately the last trimester of pregnancy.
Special Instructions
Only orderable as part of the profile FCDSU (Comprehensive Drug Screen, Umbilical Cord Tissue). Confirmation testing is performed when appropriate at no additional charge.
Limitations
Reporting limit is determined with each analysis. This assay may not differentiate between delta‑8 and delta‑9 THC or their metabolites. A negative result does not rule out maternal use during pregnancy. Detection depends on maternal usage patterns, drug stability, deposition characteristics in cord tissue, and analytical performance.
New York Approved
Methodology
Mass Spectrometry (LC-MS/MS)
Biomarkers
LOINC Codes
- 97584-7
- 97586-2
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Tissue
Volume
Not provided
Minimum Volume
Not provided
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Not provided |
| Refrigerated | 7 days (preferred) |
| Frozen | 14 days |